Miguel Chillon Rodriguez Dr. M. Chillon has been a senior ICREA researcher since 2001 and Director of the UAB-VHIR Joint Unit since 2017. He obtained his doctorate in Genetics at Hospital Duran i Reynals in 1994. Dr. M. Chillon is Director of the Production Unit of Vectors since 2004, Associate Professor at the UAB since 2005, Principal Investigator of the VHIR since 2017, Co-Chair of the Platform for Advanced Therapies of the European organization EATRIS since 2016, coordinator of the eCORE AVANT of the VHIR since 2022, and scientific advisor of different patient organizations and biotechnological spin-offs Institutions of which they are part Head of group Gene Therapy at Nervous System Vall Hebron Institut de Recerca Twitter Orcid Email Miguel Chillon Rodriguez Twitter Orcid Email Institutions of which they are part Head of group Gene Therapy at Nervous System Vall Hebron Institut de Recerca Dr. M. Chillon has been a senior ICREA researcher since 2001 and Director of the UAB-VHIR Joint Unit since 2017. He obtained his doctorate in Genetics at Hospital Duran i Reynals in 1994. Dr. M. Chillon is Director of the Production Unit of Vectors since 2004, Associate Professor at the UAB since 2005, Principal Investigator of the VHIR since 2017, Co-Chair of the Platform for Advanced Therapies of the European organization EATRIS since 2016, coordinator of the eCORE AVANT of the VHIR since 2022, and scientific advisor of different patient organizations and biotechnological spin-offs
Dr. M. Chillon created his research group in 2001 focused from the beginning on four main objectives: (1) gene therapy for cognitive deficits associated with aging; (2) gene therapy for autoimmune diseases; (3) gene therapy for rare diseases that affect the nervous system and (4) development of more efficient gene therapy vectors. Dr. Chillon is the author of 76 scientific articles, 3 reviews, 5 book chapters, editor of 1 book (H index: 27; 3470 citations, Scopus), and has directed 14 doctoral theses (4 in progress) and 22 students of Master. In the last five years, Dr. Chillon has obtained different national and international projects such as the European Joint Program-Rare Diseases AC20/00051; Society Challenges. PID2019-104034RB-I00; Challenges Collaboration RTC2019-006879-1; RICORS of the ISCIII RD21/0017/0008; Santander Foundation (2020); CERVERA IDI-2020-0258; ALS International (2018-0512); SmartMoney-UAB (2017); and Marathon TV3, 201607.10. Regarding technology transfer, Dr. Chillon's group has generated 10 patents and founded 2 spin-off companies: NanoTherapix (2009) for gene and cell therapy for diseases of the immune system; and Klogene (2016) for gene therapy of cognitive impairments. He has also founded the Vector Production Unit (UPV) to value the knowledge generated. Currently, the UPV is the first supplier of Ad and AAV vectors to Spanish groups and has the TECNIO Quality accreditation and ISO9001:2015 accreditation. Finally, in recognition of his career, Dr. M Chillón received the "Transfer Award" in 2018 from the Social Council of the UAB.
Projects Estudio del papel de la isoforma soluble de alpha-Klotho en el inicio y progresión de déficits cognitivos: marcador de diagnóstico precoz, y molécula diana con potencial terapéutico IP: Miguel Chillon Rodriguez Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 165165 Reference: PI15/01270 Duration: 01/01/2016 - 31/12/2018 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3
